Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929155 | 0.90 | CYP4F2 (0.38) | TRPA1ALDH1A1TSHR | |
| SCHEMBL2655669 | 0.85 | TDP1 (0.42) | — | |
| SCHEMBL5725208 | 0.82 | SLC5A2 (0.37) | — | |
| SCHEMBL5311499 | 0.81 | CHRNB4 (0.43) | TSHR | |
| SCHEMBL50479 | 0.81 | TSHR (0.38) | TSHR | |
| SCHEMBL8022584 | 0.79 | ALDH1A1 (0.37) | TRPA1ALDH1A1TSHR | |
| SCHEMBL6934088 | 0.78 | DRD2 (0.44) | — | |
| SCHEMBL6696772 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TSHR | |
| SCHEMBL3368136 | 0.77 | GBA1 (0.37) | ALDH1A1 | |
| SCHEMBL5311927 | 0.75 | TRPA1 (0.39) | TRPA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401263-B1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-02-17 | — | — | EP | disclosed |
| US-8828992-B2 | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-09 | — | — | US | disclosed |
| WO-2013068785-A1 | INDANONE AND INDANDIONE DERIVATIVES AND HETEROCYCLIC ANALOGS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-16 | — | — | WO | disclosed |
| EP-2401263-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK Biopharmaceuticals Co., Ltd. (KR) | 2012-01-04 | — | — | EP | disclosed |
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2011-12-08 | — | — | US | disclosed |
| EP-1812388-B1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010098600-A2 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | SK HOLDINGS CO., LTD. (KR) | 2010-09-02 | — | — | WO | disclosed |
| US-7754719-B2 | Substituted piperidine derivatives as somatostatin SST1 receptor antagonists | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS EHF (IS) | 2009-11-26 | — | — | US | disclosed |
| US-20080255142-A1 | Substituted Piperidine Derivatives as Somatostatin Sst1 Receptor Antagonists | NOVARTIS AG (CH) | 2008-10-16 | — | — | US | disclosed |
| EP-1909792-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AS SOMATOSTATIN SST1 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| EP-1812388-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | Decode Genetics (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007009662-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AS SOMATOSTATIN SST1 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20060122234-A1 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | ARGENTA DISCOVERY LIMITED | 2006-06-08 | — | — | US | disclosed |
| WO-2006044000-A1 | SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | DECODE GENETICS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | SAGA INVESTMENTS LLC | 2006-04-13 | — | — | US | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1525199-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | Argenta Discovery Limited (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004013130-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301150-A1 | SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME | MAOB, MAOA, PARK7 | TRPA1 4103/4885ALDH1A1 385/4885TSHR 2218/4885 |
| US-20060079520-A1 | Sulfonamide peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGS2 | TRPA1 826/4885ALDH1A1 903/4885TSHR 3907/4885 |
| US-20090291948-A1 | SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE | PTGIS, PTGIR, PTGS2 | TRPA1 826/4885ALDH1A1 903/4885TSHR 3907/4885 |
| US-20060122234-A1 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | HDAC1, HDAC11, HDAC2 | TRPA1 4763/4885ALDH1A1 291/4885TSHR 2644/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | TRPA1 3795/4885ALDH1A1 1202/4885TSHR 2030/4885 |
| US-20080255142-A1 | Substituted Piperidine Derivatives as Somatostatin Sst1 Receptor Antagonists | SSTR1, SSTR2, SSTR3 | TRPA1 535/4885ALDH1A1 2021/4885TSHR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.